Just three years ago, Circassia was riding high, raising £200 million ($285 million) from its initial public offering (IPO), making it the most successful European biotech stock launch ever.

Some investors may remember Niox (NIOX) in its prior incarnation as Circassia, although the change of name has not shifted the company’s emphasis on point-of-care testing for asthma. In the ...

https://doi.org/10.2307/207388 • https://www.jstor.org/stable/207388 ...

Investing.com – Finland equities were higher at the close on Friday, as gains in the Basic Materials, Utilities and Industrials ...